Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue$11.35M$11.35M+62.6% vs Q2 2016 Net Income-$83.08M-$83.08MN/M vs Q2 2016 EPS Diluted-$1.78-$1.78N/M vs Q2 2016 Operating Income-$84,600,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$60,024,000N/M Margins · derivedOperating margin-745.6%+63.6 pt vs Q2 2016
Net margin-732.3%+69.6 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 8, 2017 · 39 d after period end